BlossomHill Therapeutics (NASDAQ:BLSM) Reaches New 12-Month High – Time to Buy?

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) shares hit a new 52-week high during trading on Tuesday . The company traded as high as $17.54 and last traded at $17.22, with a volume of 69520 shares trading hands. The stock had previously closed at $16.03.

Analysts Set New Price Targets

Separately, Wall Street Zen raised BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th.

BlossomHill Therapeutics Stock Up 10.2%

Insider Transactions at BlossomHill Therapeutics

In other BlossomHill Therapeutics news, Director Orbimed Advisors Llc bought 625,000 shares of the stock in a transaction on Monday, August 10th. The stock was purchased at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the acquisition, the director owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. The trade was a 29.91% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John P. Schmid bought 6,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were acquired at an average price of $16.00 per share, with a total value of $96,000.00. Following the transaction, the director directly owned 6,000 shares in the company, valued at approximately $96,000. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 1,573,900 shares of company stock valued at $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.